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Abstract
Changes in the airway microbiome may be important in the pathophysiology of chronic lung
disease in patients with cystic fibrosis. However, little is known about the microbiome in
early cystic fibrosis lung disease and the relationship between the microbiomes from differ-
ent niches in the upper and lower airways. Therefore, in this cross-sectional study, we ex-
amined the relationship between the microbiome in the upper (nose and throat) and lower
(sputum) airways from children with cystic fibrosis using next generation sequencing. Our
results demonstrate a significant difference in both α and β-diversity between the nose and
the two other sampling sites. The nasal microbiome was characterized by a polymicrobial
community while the throat and sputum communities were less diverse and dominated by
a few operational taxonomic units. Moreover, sputum and throat microbiomes were closely
related especially in patients with clinically stable lung disease. There was a high inter-indi-
vidual variability in sputum samples primarily due to a decrease in evenness linked to in-
creased abundance of potential respiratory pathogens such as Pseudomonas aeruginosa.
Patients with chronic Pseudomonas aeruginosa infection exhibited a less diverse sputum
microbiome. A high concordance was found between pediatric and adult sputum micro-
biomes except that Burkholderia was only observed in the adult cohort. These results indi-
cate that an adult-like lower airways microbiome is established early in life and that throat
swabs may be a good surrogate in clinically stable children with cystic fibrosis without
chronic Pseudomonas aeruginosa infection in whom sputum sampling is often not feasible.
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Introduction
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene and remains one of the most frequent lethal hereditary diseases in Cau-
casian populations [1]. Although CF affects various organs, over 85% of the morbidity and
mortality of the disease are attributed to an early onset lung disease that is characterized by air-
way mucus obstruction and intermittent to chronic infection with characteristic pathogens
such as Staphylococcus aureus, Haemophilus influenza, Pseudomonas aeruginosa and Burkhol-
deria cepacia complex. This results in and chronic neutrophilic inflammation leading to
bronchiectasis and progressive lung damage [2–4].
The airways are composed of different interconnected niches, namely the nasal sinuses, the
throat and the conducting airways. Bacterial colonization in the nose and throat is considered
normal and these niches harbor a complex microbiome [5,6]. Until recently, the lower airways
were considered sterile and detection of pathogens indicative of bacterial infection [7,8]. How-
ever, culture independent methods have shown that the lungs are not sterile even in healthy
people [9,10]. In CF patients, the lungs are colonized by a polymicrobial community contain-
ing a diverse array of organisms including potential respiratory pathogens (PRPs) [9,11]. The
dynamics of the microbiome in the lower airways evolves from an initial diversification in
younger CF patients followed by a reduction and selection of PRPs frequently associated with a
decline in pulmonary function in older patient populations [12]. A similar shift from a polymi-
crobial community to a pathogen centered community linked to disease has already been de-
scribed in both the gut and oral cavity [13–15].
The lungs are the target of colonization by bacteria from the environment via the upper air-
ways (nose and throat) and thus these sites need to be explored to highlight the relationship be-
tween the different microbial ecosystems inhabiting the airways. To date, studies focusing on
this question were mostly pathogen centered. They showed that PRPs from the environment
are residents in the nasal cavity suggesting that this niche serves as a reservoir for further colo-
nization via micro-aspiration in the lower airways [16,17]. PRPs persist in the nasal cavity and
can re-colonize after antibiotic treatment giving raise to chronic infection in young CF patients
[18,19]. However, to date, microbiome composition in the early stages of CF lung disease and
the relationship between the microbiome at different niches of the upper and lower airways
have not been studied in detail using next generation sequencing.
The objective of this study was to compare the microbiome of the nasal cavity, throat and
sputum in young CF patients with mild to moderate lung disease. The first objective was to
compare the three microbial ecosystems and determine potential differences in bacterial com-
position. The second objective was to explore the inter-individual variation between micro-
biomes in the upper and lower airways. We also compared the microbiome from young and
adult CF patients to determine the onset and dynamics of abnormal microbiome composition
in CF.
Materials and Methods
Pediatric CF patients
This prospective observational study was approved by the Ethics Committee of the University
of Heidelberg and informed written consent was obtained from the patients, parents or legal
guardians of all subjects. Airway samples from pediatric CF patients were obtained during rou-
tine visits every three months at periods of clinically stable lung disease or during acute pulmo-
nary exacerbations. Patient characteristics are summarized in Table 1 and in S1 Table. In total,
98 samples (sputum, n = 32; nasal swabs, n = 36; throat swabs, n = 30) were analyzed. In all
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patients, the diagnosis of CF was based on characteristic clinical symptoms and confirmed by
increased sweat Cl- concentrations (60 mmol/L) and CFTR mutation analysis (S2 Table),
and in 3 pancreatic-sufficient patients with borderline sweat test results by assessment of CFTR
function in rectal biopsies according to established diagnostic criteria as previously described
[20,21]. Anthropometric data of CF patients are provided in Table 1. Z-scores for weight,
height, and BMI were derived from reference values of healthy children in Germany [22,23].
The status regarding infection with Pseudomonas aeruginosa was classified according to the
following definition as negative, intermittent or chronic infection [24,25]: Patients were catego-
rized as P. aeruginosa negative, when there was no growth of P. aeruginosa in the previous
twelve month and titers of precipitating antibodies (alkaline protease, elastase and exotoxin A)
(Mediagnost, Reutlingen, Germany) against P. aeruginosa antigens were negative. Intermittent
P. aeruginosa infection was defined as culturing of P. aeruginosa in less than 50% of the sam-
ples in the last twelve month and negative antibodies. Chronic P. aeruginosa infection was de-
fined as persistent presence of P. aeruginosa for at least 6 consecutive months, or less when
combined with a positive finding (titer>1500) of two or more P. aeruginosa antibodies.
Adult CF patients cohort
Details of the adult CF patient cohort in this study were included in two previously published
studies in which the airway microbiome was analyzed by extended aerobic and anaerobic bac-
terial culture, terminal restriction fragment length polymorphism (T-RFLP) analysis and high-
throughput 454-FLX Titanium pyrosequencing of bacterial 16S rRNA marker genes present in
sputum [26,27].
Routine culture
All samples (ESwabs) were streaked and incubated for 24h and 48h at 36°C (6% CO2) on vari-
ous media. Five media were used for aerobic isolation: Columbia-Agar (with 5% sheep blood)
(BD Diagnostic, Heidelberg, Germany), Chocolate-Agar (BioMérieux, Nürtingen, Germany),
McConkey- Agar (BioMérieux), Burkholderia cepacia-Spezial-Agar (7 days, 36°C) (BD),
Table 1. Patients’ characteristics.
mean ± SD (range) or n (%)
Number of patients 20
Age, years 16.1 ± 3.8 (7.0–22.0)
Male/female 8/12
F508del / F508del, n (%) 9 (45)
Pancreatic insufﬁciency, n (%) 17 (85)
Weight, kg 47.9 ± 9.4 (23.7–63.3)
Weight, SDS -1.4 ± 1.3 (-4.1–0.1)
Height, cm 159.8 ± 11.9 (126.6–180.0)
Height, SDS -1.3 ± 1.3 (-3.9–0.5)
BMI, kg/m2 18.6 ± 2.1 (14.8–23.2)
BMI, SDS -0.8 ± 0.9 (-2.2–0.7)
FEV1, % pred. 70.5% ± 24.5% (33.9%–111.2%)
LCI 14.4 ± 2.9 (9.1–19.8)
BMI, body mass index; FEV1% pred, forced expiratory volume in 1 second % predicted; LCI, lung
clearance index, SDS standard deviation score
doi:10.1371/journal.pone.0116029.t001
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Sabouraud- Agar (7 days, 36°C) (BD). Additionally, two media were used for anaerobic isola-
tion (36°C): Schaedler-Agar (BioMérieux) and Kanamycin-Vancomycin-Agar (BD). Anaero-
bic cultures were processed within an hour after receiving the sample. Once colonies were
isolated, they were identified with a Microflex MALDI-TOF mass spectrometer (Bruker
Daltonik, Bremen, Germany) [28].
Sample pre-treatment
Samples were aliquoted (200μL) and treated with PMATM dye (Biotium Inc., Hayward, USA).
PMA treatment modifies extracellular DNA from dead cells and avoids subsequent PCR
amplification. 50μM of PMA dye was added to the aliquot and incubated for 5 min in the dark.
The samples were then exposed to light (650 Watt, 20 cm distance to the samples) on ice and
shaking by 100 rpm for 5 min to cross-link PMA to DNA. Viable cells were pelleted by centri-
fugation at 5000 x g for 10 min. Supernatant was removed and cells were recovered in 200 μL
of sterile PBS and stored at -20°C until DNA extraction.
DNA extraction
DNA extractions were performed using the QIAamp Mini Kit (QIAGEN, Hilden, Germany).
Protease solution (7.2 mAU) and 200 μL of Buffer AL were added to the sample followed by a
15 sec vortex. Samples were incubated at 56°C for 10 min and then purified according to the
manufacturer’s protocol. DNA was eluted by adding 100 μL of buffer AE to the column, incu-
bation for 1 min at room temperature and centrifugation at 6000 x g for 1 min. Negative con-
trols were performed by doing the extraction without clinical samples.
Quantitative PCR
The number of 16S copies was quantified by quantitative PCR (qPCR) using Unibac primer
(forward: 50-TGG AGC ATG TGG TTT AAT TCG A-30; reverse: 50-TGC GGG ACT TAA
CCC AAC A-30). PCR reactions were performed in 15 μL volumes composed of 1X Sybr-green
mastermix (Life technology, Darmstadt, Germany), 50 pmol of each primer and 2 μL of DNA
(or plasmid DNA standards). The thermal cycler conditions were: a first denaturation at 95°C
for 20 sec, 40 amplification cycles (95°C for 3 sec, 60°C for 30 sec) and two final steps at 95°C
for 15 sec and 60°C for 1 minute followed by a melt curve. All reactions were performed in du-
plicate in a 7900HT Fast Real-time PCR system (Applied Biosystems, Foster City, USA).
Quantification of the 16S number of copies was performed by comparison to the Cycle thresh-
old value of a plasmid DNA standard which had been cloned in-house and quantified by
spectrophotometry [29].
Library preparation for next generation sequencing (NGS)
DNA was amplified using universal bacterial primers flanking the V6 region (v6L and v6R,
taken from [30]). Each primer was tagged with an individual barcode to assign the sequences
to the samples. PCR reactions were performed in 25 μL volumes composed of 1X FastStart
Master mix (Roche Diagnostics Deutschland GmbH, Mannheim, Germany), 50 pmol of each
primer and 2 μL of DNA. The thermal cycler (Primus 25, Peqlab Biotechnologie GmbH, Ger-
many or FlexCycler², Analytik Jena AG, Germany) conditions were: a first denaturation at
94°C for 5 min, 32 amplification cycles (94°C for 45 sec, 52°C for 1 min and 72°C for 1 min
30 sec) and a final extension at 72°C for 10 minutes. PCR products were then checked on an
agarose gel (2%) and concentrations were determined by comparing the intensity of the bands
to intensity of the standards. Amplicons were purified by using a QIAquick PCR purification
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kit (QIAGEN). Purified products were checked for quality and concentration using a ND-1000
Nanodrop instrument (Nanodrop, Wilmington, USA) and Bioanalyser (Agilent Technologies
Inc., Böblingen, Germany). Equimolar mix of all the PCR products (n = 98) was then sent to
the Center for “Quantitative Analysis of Molecular and Cellular Biosystems” at Heidelberg
University (BIOquant). Ligation of the sequencing adapters to the library was done by standard
procedures and the library was paired-end sequenced on an Illumina Hiseq system.
A negative control for the extraction was done using sterile water instead of clinical sample
to ensure that no contamination occurred. This negative control was then used as template
during the PCR to verify absence of bacterial DNA. Furthermore, we also used sterile water as
template for a negative control of the PCR reaction itself. No bands were observed when the
negative controls were checked on an agarose gel.
Analysis of sequences
Raw sequences were first filtered for quality; sequences with a quality score lower than 25 over
90 bp were discarded. The right and left paired-end sequences were then synchronized and or-
phan reads were discarded. The paired reads were merged in contigs and contigs were assigned
to the sample with the barcodes on the right and left ends (allowing a mismatch of 1 nt per bar-
code). The assignment and the pre-treatment of the sequences were done using MOTHUR
software (version 1.33) [31]. Sequences were screened for ambiguity in the sequences (maxi-
mum ambiguity allowed: 0) and for homopolymers (maximum homopolymer length allowed:
4 nt). Chimera detection was done by using the algorithm Uchime [32] which allows a fast,
sensitive and accurate detection of chimera. Sequences were then clustered as Operational Tax-
onomic Units (OTU) (using the threshold of 3% of divergence) and OTU representative se-
quences were then classified at the taxonomic levels by comparisons with sequences from the
SILVA database (cutoff set to 80% of similarity). Furthermore, OTU abundances for each sam-
ple were calculated to build an OTU table. All sequences data are available on MG-RAST server
(MG-RAST IDs: XXXXX).
Statistical analysis
An OTU table was used to calculate descriptive indices for alpha-diversity (non-parametric
Shannon index), richness (Chao1 richness estimate) and evenness (Shannon index-based mea-
sure of evenness). Variation in the alpha-diversity among samples was tested with a linear
mixed model with random effects for patients due to the inter-individual differences existing
between patients. Paired comparisons were done with a post-hoc test [33,34]. Beta-diversity
measures were performed to examine the differences between the samples. Principal compo-
nent analysis (PCA) was performed directly on the OTU table to analyze how the samples were
related. Distance matrices were constructed based on index of similarity of community mem-
bership and structure with distances and structure estimated with the Jaccard and Bray-Curtis
indices, respectively. An analysis of similarities (ANOSIM) was performed to validate the sta-
tistical significance of the changes among samples. These changes were visualized by a PCoA
(Principal coordinate analysis) and influences of each OTU on the differentiation of the sam-
ples were calculated by the Pearson correlation between the OTU abundance/presence and the
coordinate of the samples on the different axis of the PCoA. We also performed a linear dis-
criminant analysis (LDA) effect size (LEfSe) analysis to detect differentially abundant OTU be-
tween the samples. Correlation between OTU and clinical data was calculated with Pearson
correlation between all variables and results were corrected for multiple testing. A mantel test
between the similarity distance matrix (based on Bray-Curtis index and on Jaccard index) and
a distance matrix based on culture data (euclidian distance) was performed to see if any
CF Airway Microbiomes at Different Sampling Sites
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relationship existed between microbiome and the detection of PRPs by culture. As inter-indi-
vidual variation was important in our data, we assigned samples to ecotypes using a Dirichlet
multinomial mixture (DMM) model [35] and analyzed the relationships between partitioning
and the clinical data. The ecotype assignment clustered similar samples in the same partition.
We considered in this model that microbial communities sharing a high degree of similarity
belong to the same community type (ecotype). We calculated the accuracy of this clustering
using the Dirichlet probabilistic distribution [35]. For each categorical clinical data, we tested
the association on a contingency table using Fisher’s exact test and continuous data were tested
using ANOVA. All statistical analyses were performed with MOTHUR 1.33.0 and R 3.0.2.
Results
Quality of the sequencing dataset from CF samples
A total of 122,611,422 reads were obtained and passed through quality filter and chimera detec-
tion resulting in 94,177,638 (76.8%) clean and non-chimeric reads. These reads were unevenly
distributed among the samples (Fig. 1A) and the whole data set was normalized by subsam-
pling the same number of reads for each sample (154,849 reads per sample). Reads were clus-
tered in 295,617 OTUs (using a threshold of 97% identity) but most of the OTUs were
represented by few reads. We sorted the data to filter any OTUs that did not reach 0.001% of
the sample microbiome. Thus, 76 OTUs were retained and assigned to the taxonomic level
(Fig. 2, S1 Fig.). Taxonomy was validated or improved by a blast on NCBI database (using a
threshold of 99% identity). The coverage of our sequencing was assessed by rarefaction curves
and computing the Good’s estimator of coverage (S1 Table, S2 Fig.). Each sample’s curve
reached a plateau and the Good’s estimator of coverage was always higher than 94%.
Comparison of NGS with culture analysis
In total, 18 genera were found by culture as compared to 76 frequent OTUs by NGS. From all
specimens (nose, throat and sputum) included in the study, only two samples coming from the
nose were classified as sterile with no aerobic or anaerobic bacteria detected by culture. The
Fig 1. Descriptive analysis of the sequencing reads. (A) Distribution of the number of reads over the whole dataset. (B) Number of samples with detection
of the indicated percentage of the microbiome at the genus level by culture. Strains isolated by culture were classified at the genus level and correspondence
with the NGS dataset was analyzed.
doi:10.1371/journal.pone.0116029.g001
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other samples were positive for one to seven different genera. We compared the number of
genera detected by culture with the relative abundance of those genera in the NGS dataset
(Fig. 1B); of 98 samples, 45 showed less than 50% detection by culture as compared to NGS.
These samples were mostly colonized by OTUs including Phyllobacterium sp., Ralstonia sp.,
Microbacterium sp. or Corynebacterium sp. that we failed to detect by culture despite the nu-
merous media and conditions used. In contrast, in 38 samples, over 70% of genera detected by
NGS were also detected by culture. These samples were colonized by classical PRPs such as
Staphylococcus sp., Pseudomonas sp., and anaerobic genera such as Prevotella sp. and Veillonella
sp. that our aerobic and anaerobic culture methods can easily detect. Overall, the mantel test
comparing microbiome data obtained by NGS and PRPs detection by culture showed a signifi-
cant but weak correlation between the two datasets (r = 0.30, p-value< 0.001).
Microbiome analysis in clinically stable children with CF
We first analyzed samples that were obtained from pediatric CF patients with clinically stable
lung disease obtained during routine visits. The alpha-diversity differed among the samples
and between the three sampling sites (Fig. 3A) with the nasal microbiome showing a higher
Fig 2. Relative abundance of the bacterial genera depending on the sampling site. The colored segments of each bar represent the proportion of reads
mapping to different bacterial genera.
doi:10.1371/journal.pone.0116029.g002
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diversity compared to throat and sputum microbiomes. The richness and the evenness were
analyzed to see if the observed divergence was consistent on these two components of the
alpha-diversity (Fig. 3B, C). The pattern observed was the same for the three analyses with a
divergence of the nasal microbiome (p<0.01) and no difference between throat swabs and spu-
tum. These analyses demonstrated that microbial communities from the nose were character-
ized by an even polymicrobial assemblage, while sputum and throat microbiomes showed
lower evenness and diversity. In nasal samples, a negative correlation (r< -0.4, p-value<0.05)
was found between evenness and three different OTUs classified as Enterobacteriaceae, Ralsto-
nia sp. and Pseudomonas aeruginosa. In contrast, a positive correlation (r> 0.4, p-value<
0.05) was found between evenness and seven OTUs belonging to Variovorax sp., Acinetobacter
sp., Flavobacterium sp. (2 OTUs),Microbulbifer sp., Acidovorax sp. and Pelomonas sp.
Increased bacterial load in CF patients is correlated with decreased
diversity
A negative correlation was found between the total bacterial load, as assessed by numbers of
copies of 16S gene, and both the non-parametric Shannon index (r = -0.61, p-value = 1.544e-
11) (Fig. 4A) and evenness (r = -0.62, p-value = 9.649e-12) (Fig. 4B) indicating that increased
microbial colonization is associated with a decrease in diversity. This finding is supported by
the fact that evenness decreased with acute pulmonary exacerbations when a PRP (P. aerugi-
nosa in our study) was detected. No correlation was found between the number of copies of
16S and the chao1 richness estimate (r = 0.06, p-value = 0.6928). Despite results found in adults
[12], we found no correlation between richness (chao1 richness estimate: r = 0.04, p-value =
0.7805), evenness (r = -0.13, p-value = 0.3934) or overall alpha-diversity (r = -0.13, p-value =
0.4084) with patient age in our pediatric CF cohort (data not shown).
Nasal CF microbiome structure differs from throat and sputum
microbiome
As the three sampling sites showed divergence in the alpha-diversity, we next analyzed the
beta-diversity to depict this divergence and assess its accuracy. The principal component
analysis (PCA) showed that nasal samples from clinically stable CF patients can be easily dis-
criminated from throat and sputum samples (Fig. 5A). Discrimination was even stronger if we
Fig 3. Alpha-diversity of the upper and lower airwaysmicrobiomes from clinically stable children with CF. Alpha-diversity was calculated with the non
parametric Shannon index (A), richness was estimated with the Chao1 estimate (B) and evenness was calculated based on the Shannon index (C). Alpha-
diversity variation among nose, throat and sputummicrobiome was analyzed with a linear mixed model with random effects for CF patients and paired
comparisons were done with a Tukey post-hoc test for pairwise comparison.
doi:10.1371/journal.pone.0116029.g003
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included samples collected during exacerbation (Fig. 5B). Axis 1 in the PCA did not completely
discriminate the three sampling sites but was the most discriminating axis among samples.
This axis was correlated strongly with the abundance of one OTU classified as P. aeruginosa.
Axis 2 was the most discriminating dimension regarding the three sampling sites and is corre-
lated with three OTUs. Two OTUs, namely Phyllobacterium sp. and Ralstonia sp., were mostly
abundant in nasal samples while the third OTU, Streptococcus sp., was more prevalent in throat
and sputum samples. The same result was found with PCoA based on the Bray-Curtis index.
Bray-Curtis index takes into account the abundance of each OTU (i.e. structure of the micro-
biome) and estimates of the dissimilarity of the samples. This analysis also showed a divergence
between the structure of the microbiome in the nose and both throat and sputum (Fig. 5C and
Fig 4. Correlation between alpha-diversity and bacterial load in CF airways. The alpha-diversity is
represented by the non parametric Shannon index (A) and the evenness index based on the Shannon index
(B). The microbial load was measured via the proxy of the number of 16S genes. Samples from the three
sampling sites are represented.
doi:10.1371/journal.pone.0116029.g004
CF Airway Microbiomes at Different Sampling Sites
PLOS ONE | DOI:10.1371/journal.pone.0116029 January 28, 2015 9 / 19
5D). Furthermore, an analysis of similarities (ANOSIM) showed that nose microbiomes are
significantly different from the two others (r-value = 0.663 and 0.63, p-value< 0.001), while
microbiomes from throat and sputum did not differ (r-value = 0.039, p-value = 0.237).
A PCoA based on the Jaccard index was performed to analyze differences in the composi-
tion of the different microbiomes. The Jaccard index is a similarity coefficient which does not
take into account the abundance of the OTUs but rather relies on presence/absence of OTUs
(i.e. the composition of the microbiome). No differences were observed on the PCoA based on
Fig 5. Spatial analysis of the airways microbiome. Nasal swabs are represented by black dots, throat swabs by red dots, sputum samples by green dots.
(A) Principal Component Analysis of samples obtained from clinically stable children with CF. In panel (B) samples from patients during exacerbation were
added. Pearson correlations were performed to highlight which OTUs were responsible for the divergence among the samples. Correlation was considered
significant when the coefficient of correlation was higher than 0.6 and p-value< 0.01. (C) Principal Coordinates Analysis was performed on samples obtained
from clinically stable CF patients or (D) on all available samples from CF patients irrespective of the clinical status.
doi:10.1371/journal.pone.0116029.g005
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Jaccard index. ANOSIM analysis confirmed this observation with no overall significant
variation among the three sampling sites (R-value = 0.002, p-value = 0.423).
OTU differences between nasal, throat and sputummicrobiomes in CF
patients
The divergence between nasal and throat microbiomes was based upon 28 OTUs from the 76
most abundant OTUs classified in 23 genera (Table 2). The top 5 abundant OTUs in the nasal
microbiome were Otu044237 (Ralstonia sp., 17.5%), Otu093761 (Microbacterium sp., 14.1%),
Otu294556 (Phyllobacterium sp., 13.4%), Otu164280 (Streptococcus sp., 10.1%), Otu042022
(Enteric Bacteria cluster, 6.3%). The throat microbiome was dominated by two major OTUs;
Otu164280 (Streptococcus sp., 24.1%) and Otu263762 (Prevotella sp., 18%). The divergence
between the nasal and sputum microbiomes was based upon 28 OTUs classified in 23 genera
(Table 2). The sputum microbiome was dominated by two OTUs: Otu044227 (P. aeruginosa,
15.1%) and Otu263762 (Prevotella sp., 9.6%). The same divergent OTUs were found between
the nose and both sputum and throat (21 divergent OTUs in common) strengthening the close
relationship between throat and sputum. This result is confirmed by the small numbers of
OTUs found divergent between throat and sputum with only eight OTUs present in low
abundance except for the Streptococcus genus (Table 2).
Comparison of microbiome composition in pediatric versus adult CF
patients
In order to explore if this inter-individual variation observed between CF patients was age-depen-
dent, we compared our data obtained from sputum samples from pediatric CF patients with data
from a cohort of adult CF patients [26,27]. Each OTU was classified at the genus level and both
datasets were compared by means of a PCA. This comparison showed striking convergence,
except for one group of adult patients highly infected by Burkholderia. Similar to pediatric CF
patients, the adult CF cohort showed a clustering in different ecotype dominated either by Pseu-
domonas or Streptococcus. Furthermore, high inter-individual variation was also found in adults
with patients dominated by either Pseudomonas, Streptococcus or Burkholderia (Fig. 6).
Ecotype assignment identifies chronic Pseudomonas infection as
decisive variable for microbiome diversity
The ecotype assignment was consistent with the PCA results. Two partitions were found for
both samples coming from nose and sputum reflecting the inter-individual variability observed
in the PCA and only one cluster for the throat samples. The nasal partitions were different
mostly regarding the diversity and the evenness. Some patients (ecotype 2) exhibited a highly
diverse and even nasal microbiome while other patients (ecotype 1) showed low diversity
microbiome dominated by two OTUs; Otu044237 (Ralstonia sp.) and Otu294556 (Phyllobac-
terium sp.) which accounted for 74.3% of the microbiome. The same pattern was observed in
the sputum partitioning, with some patients (ecotype 2) possessing a highly diverse and even
microbiome where the predominant OTUs belonged to Streptococcus sp. and Prevotella sp. and
did not exceed 10% of the microbiome. In contrast, patients in ecotype 1 were primarily in-
fected by one OTU (Otu044227; P. aeruginosa) which accounted for 73.4% of the microbiome
(Fig. 7). We found a strong correlation (p-value< 0.001) between the sputum ecotype assign-
ment and the classification of chronic infection by P. aeruginosa. Of note, patients belonging to
sputum ecotype 1 were most likely classified as patients suffering of chronic infection with
Pseudomonas aeruginosa.
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Table 2. Differential abundance of the most abundant OTUs among the different sampling sites.
OTU difference between
nose and sputum
difference between
nose and throat
difference between
sputum and throat
Taxonomy
Otu009303 no Throat Throat Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;
Streptococcus
Otu032767 Sputum Throat No Firmicutes;Bacilli;Lactobacillales;Carnobacteriaceae;
Granulicatella
Otu039334 no Nose No Actinobacteria;Actinomycetales;Corynebacteriaceae;
Corynebacterium
Otu040700 Sputum Throat No Actinobacteria;Actinobacteria;Coriobacteriales;
Coriobacteriaceae;Atopobium
Otu042022 no Nose No Proteobacteria;Gammaproteobacteria;Enterobacteriales;
Enterobacteriaceae;Enteric_Bacteria_cluster
Otu044227 no no No Proteobacteria;Gammaproteobacteria;Pseudomonadales;
Pseudomonadaceae;Pseudomonas;aeruginosa
Otu044237 Nose Nose No Proteobacteria;Betaproteobacteria;Burkholderiales;
Burkholderiaceae;Ralstonia
Otu048236 Sputum no No Actinobacteria;Actinomycetales;Micrococcineae;
Micrococcaceae;Rothia
Otu050175 Nose Nose Throat Proteobacteria;Betaproteobacteria;Burkholderiales;
Comamonadaceae;Pelomonas
Otu054786 Nose Nose No Proteobacteria;Alphaproteobacteria;Caulobacterales;
Caulobacteraceae;Brevundimonas
Otu059814 Sputum no Sputum Actinobacteria;Actinomycetales;Micrococcineae;
Micrococcaceae;Rothia
Otu063017 Nose Nose Throat Proteobacteria;Betaproteobacteria;Burkholderiales;
Comamonadaceae;Variovorax
Otu093761 Nose Nose No Actinobacteria;Actinomycetales;Micrococcineae;
Microbacteriaceae;Microbacterium
Otu106057 Nose Nose No Proteobacteria;Gammaproteobacteria;Pseudomonadales;
Moraxellaceae;Acinetobacter
Otu110859 Nose Nose No Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;
Lactobacillus;sakei
Otu113401 Sputum Throat No Firmicutes;Clostridia;Clostridiales;Veillonellaceae;Veillonella
Otu133067 Nose Nose no Proteobacteria;Betaproteobacteria;Burkholderiales;
Comamonadaceae;Comamonas
Otu134395 Nose Nose no Bacteroidetes;Flavobacteria;Flavobacteriales;
Flavobacteriaceae;Flavobacterium
Otu164280 no Throat Throat Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;
Streptococcus
Otu172150 Nose Nose no Proteobacteria;Betaproteobacteria;Burkholderiales;
Comamonadaceae;Diaphorobacter
Otu211292 Nose Nose no Proteobacteria;Gammaproteobacteria;Alteromonadales;
Alteromonadaceae;Microbulbifer
Otu220996 Nose no Throat Proteobacteria;Betaproteobacteria;Burkholderiales;
Comamonadaceae;Acidovorax
Otu222581 Sputum Throat no Firmicutes;Clostridia;Clostridiales;Veillonellaceae;Veillonella
Otu241870 Nose Nose no Proteobacteria;Gammaproteobacteria;Xanthomonadales;
Xanthomonadaceae;Stenotrophomonas
Otu242798 Nose Nose no Proteobacteria;Alphaproteobacteria;Rhizobiales;
Brucellaceae;Ochrobactrum
Otu252790 Sputum no no Fusobacteria;Fusobacteria;Fusobacteriales;
Fusobacteriaceae;Fusobacterium
Otu259630 Nose Nose no Bacteroidetes;Sphingobacteria;Sphingobacteriales;
Cytophagaceae;Arcicella
(Continued)
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Discussion
Human airways are characterized by interconnections between highly compartmentalized
environmental niches (nose, throat and lungs). In this study, we used, for the first time to
our knowledge, massive parallel sequencing to determine relationships between different
Table 2. (Continued)
OTU difference between
nose and sputum
difference between
nose and throat
difference between
sputum and throat
Taxonomy
Otu260625 Nose Nose Throat Proteobacteria;Betaproteobacteria;Burkholderiales;
Comamonadaceae;Pelomonas
Otu261770 no no Throat Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;
Streptococcus
Otu263762 no no no Bacteroidetes;Bacteroidia;Bacteroidales;Prevotellaceae;
Prevotella
Otu264082 Sputum Throat no Proteobacteria;Epsilonproteobacteria;Campylobacterales;
Campylobacteraceae;Campylobacter
Otu265054 Nose Nose no Proteobacteria;Betaproteobacteria;Burkholderiales;
Comamonadaceae;Comamonas
Otu275373 Nose Nose no Bacteroidetes;Flavobacteria;Flavobacteriales;
Flavobacteriaceae;Flavobacterium
Otu276093 Sputum Throat no Firmicutes;Bacilli;Bacillales;Family_XI_Incertae_Sedis;
Gemella
Otu294556 Nose Nose no Proteobacteria;Alphaproteobacteria;Rhizobiales;
Phyllobacteriaceae;Phyllobacterium
Signiﬁcance of the difference was calculated with LEfSe algorithm (FDR correction) and the site with the higher abundance is indicated. OTUs showing no
differences between all the sites are not represented in the table except for two most abundant OTUs (Otu044227 and Otu263762).
doi:10.1371/journal.pone.0116029.t002
Fig 6. Principal Component Analysis of sputum samples from children and adult patients CF patients.
Sputum samples from children with CF are represented by red points and adult CF patients by blue (at the
time of admission in the clinic) and green points (after antibiotics treatment). Pearson correlations were
performed to highlight which genera were responsible for the divergence among the samples. Correlation
was considered significant when the coefficient of correlation was higher than 0.6 and p-value< 0.01.
doi:10.1371/journal.pone.0116029.g006
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compartments of the upper and lower airways, i.e. nose, throat and sputum, in children and
adolescents with CF. A general observation was the weak concordance between culture-depen-
dent and NGS analysis of the microbiome (Fig. 1). Limitations in handling and processing of
the samples may account for the differences as some studies showed that a high percentage of
the sputum microbiome can be cultured under optimized conditions [27,36,37]. However, our
results suggest that samples analyzed within a routine setting at a university microbiology labo-
ratory lack a considerable number of bacteria and that NGS analysis may be superior for diag-
nostic characterization of polymicrobial CF airways infections in the near future.
Our first important result is that the microbiome composition in the nose differed consider-
ably from corresponding throat and sputum samples. This divergence was based on both the
alpha-diversity and the structure of the microbial community (Fig. 3 and Fig. 5). This diver-
gence between upper airways and lower airways in CF patient is concordant with the findings
of previous studies using culture-dependent analysis in CF or NGS in healthy patients [11,38].
As the nasal cavity is the first compartment of the respiratory system that is in close contact
with the environment this might account for higher diversity. This assumption of an environ-
mental origin for bacterial colonization was previously detailed in other studies focusing on
P. aeruginosa [16,19] which support our hypothesis. Previous reports showed that the nasal
cavity and paranasal sinuses can serve as a reservoir for PRPs, thus building a niche for PRP’s
in a highly polymicrobial community with few selection pressures from antibiotic treatment
[16,39]. Nose microbiota is highly even regarding the membership (median evenness = 0.66)
indicating that competition among the different bacteria is low or reaches a stable state as
found in healthy children [40]. The same pattern was observed in our CF cohort with a signifi-
cant reduction in evenness during exacerbation (0.66 to 0.41) indicating that evenness in the
nasal cavity is important for stability. When evenness was decreased, nasal cavities were over-
colonized by three different OTUs depending on the patient (Enteric bacteria, Ralstonia sp.
and P. aeruginosa). This indicates that when dysbiosis occurs opportunistic bacteria overgrow.
Interestingly, the three major competitors observed in our study are known to be pathogens in
Fig 7. Differential mean raw abundance of Pseudomonas aeruginosa between the two ecotypes of
sputum samples.Mean raw abundance of Pseudomonas aeruginosa in sputum samples from both
ecotypes are represented by the raw numbers of reads in the sample. Statistical differences were assessed
by aWilcoxon test.
doi:10.1371/journal.pone.0116029.g007
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CF patients [19,39,41–43]. Of note, the most abundant OTUs found in the nose belong to
known typical or atypical CF pathogens, the latter comprising Ralstonia sp., Phyllobacterium
sp. andMicrobacterium sp. As those bacteria are environmental bacteria and possible contami-
nants, we examined correlation between those bacteria and biomass. If those bacteria were
only present in low biomass samples, this might indicate contamination. However, no correla-
tions were found between biomass and the abundance of those bacteria and a variety of internal
negative controls were indeed negative. These results suggest that CF pathogens are already
contained in the upper airways microbiome at times when patients are clinically stable and
may expand when local defense mechanisms are impaired and then contribute to lower airways
infection. This result is strengthened by a previous study of Maughan et al. who found those
bacteria in surgically resected lungs from CF and non-CF patients [44].
We also demonstrate that the microbiome composition of the throat and the sputum were
overall highly similar (Fig. 5). However, we found eight OTUs which are discriminant between
throat and sputum. The high similarity between throat and sputum raises the question about
contamination of sputum from the throat. Previous studies have demonstrated that CF sputum
and oral samples had distinct bacterial communities supporting the hypothesis that oral con-
tamination has a minimal impact on the assessment of airway samples from CF patients [45].
Furthermore, precautions were taken to control for contamination in two important steps of
the molecular process, namely extraction of the DNA and PCR reaction.
Indeed in stable patients characterized by the sputum ecotype 2, throat and sputum micro-
biome are closely related and present a more diverse and stable community less prone to
chronic infection by P. aeruginosa. This microbiota is dominated by Streptococcus, Prevotella
and Veillonella. Those genera were also characterized as classical commensal of the lung in
healthy non-smokers in a previous study [10]. For those patients our results suggest that throat
sampling may be a good surrogate in clinically stable patients without chronic P. aeruginosa in-
fection. Patients belonging to the sputum ecotype 1 on the other side showed a decreased simi-
larity between throat and sputum. This decrease is due to the high disturbance in the sputum
while the throat microbiota seems to be more resistant. In the sputum, we observed an increase
of P. aeruginosa and a decrease in the alpha-diversity. This interpretation is also supported in
our study by the negative correlation between the number of 16S copies found in the sample
and the alpha-diversity indicating that the over-growth of one species greatly increases bacteri-
al load and disturbs the stability of the microbiota (Fig. 2). This scenario has also been observed
for other CF pathogens (Achromobacter xylosoxidans, Pandoreae apista), where the alpha-
diversity decreased due to the over-growth of one species, which in turn was associated with
poorer lung function [46,47].
In adults, some patients showed a microbiota highly similar to the ecotype 1 observed in
children while other were subject to an over-growth of P. aeruginosa or Burkholderia sp. in a
subgroup of infected patients resulting in a third ecotype. Previous reports already showed that
pathogens from the Burkholderia cepacia complex are more prevalent in adults than children
[19]. The fact that children with CF exhibit a microbiome close to adult CF patients indicates
that the abnormal microbiome observed in adult CF patients compared to healthy people is
probably established early in life. However, future longitudinal studies will be required to deter-
mine the sensitivity and specificity of microbiome analyses in distinguishing intermittent from
chronic Pseudomonas infection in patients with CF (Fig. 6).
In conclusion, we demonstrate that the microbiome of the nose differs substantially from
the throat and the lower airways in children with CF. Further, we demonstrate that the micro-
biomes of the throat and sputum are closely related in clinically stable children with CF indicat-
ing that throat swabs may be a surrogate for the lower airways microbiome in Pseudomonas
negative young children with CF who are not able to expectorate sputum. Finally, we
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demonstrate that an abnormal microbiome characteristic of adult CF patients with advanced
lung disease is already established in children with CF, suggesting that changes in microbiome
structure may occur early in the pathogenesis of CF lung disease. Analysis of the sputum
microbiome may be informative for discrimination between intermittent and chronic infection
with Pseudomonas aeruginosa, an issue that has important diagnostic and therapeutic implica-
tions but remains difficult to solve by culture-dependent diagnostics [24,48,49]. In future work,
it will therefore be interesting to study longitudinal samples from the different airway niches in
patients with CF to determine whether PRPs established in the upper airways can subsequently
colonize the lungs and whether this depends on the microbiome ecotype.
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